VNRX-5024(VNRX-5024) - 药物靶点：β-lactamase_专利_临床

概要

基本信息

药物类型

小分子化药

别名

VNRX 5024

靶点

β-lactamase

作用方式

抑制剂

作用机制

β-lactamase抑制剂(β-内酰胺酶抑制剂)

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Venatorx Pharmaceuticals, Inc.

在研机构-

非在研机构-

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 VNRX-5024 相关的临床试验

NCT04877379

/ Completed临床1期

VNRX-7145-102: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics (PK) of VNRX-7145 and VNRX-5024 (Ceftibuten) in Healthy Adult Volunteers

This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024 (ceftibuten) when administered as single agents and with co-administration in a single dose cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8 hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3.

开始日期2021-06-08

申办/合作机构

Basilea Pharmaceutica AG

[+1]

NCT04314206

/ Completed临床1期

A Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5024 Administered Orally for 10 Days in Healthy Adult Volunteers

This is a 2-part dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-5024. Subjects will be enrolled in one of three dose cohorts. They will receive a single dose on Day 1 in Part 1 and will proceed into the multiple dose Part 2 of the study after safety assessments and PK samples are collected. In the multiple dose part of the study, subjects will receive multiple doses of VNRX-5024 for 10 days.

开始日期2020-07-27

申办/合作机构

Basilea Pharmaceutica AG

[+1]

100 项与 VNRX-5024 相关的临床结果

登录后查看更多信息

100 项与 VNRX-5024 相关的转化医学

登录后查看更多信息

100 项与 VNRX-5024 相关的专利（医药）

登录后查看更多信息

100 项与 VNRX-5024 相关的药物交易

登录后查看更多信息